Global Expansion Simbec-Orion is expanding footprints in North America and Europe, including Cambridge MA and Cambridge UK, plus Broadway, VA, enabling multi-region trial management and closer collaboration with biotech clusters.

Full Service CRO As a global, full-service CRO, the company offers end-to-end clinical development from First-in-Human to post-marketing with flexible, tailor-made, scalable solutions for small and mid-size drug developers, across clinical pharmacology, oncology, and rare diseases.

Data Science Edge Investments in data science leadership and a partnership with Biotx.ai signal a strong focus on causal modelling and data-driven trial design, enabling optimized development plans and potential cost/time efficiencies for sponsors.

Immunoassay Expansion Recent lab investments, including a second Ella ELISA analyser, enhance immunoassay capabilities for pharmacokinetics and biomarker work, supporting robust analytical data in trials.

Therapeutic Focus Deep expertise in oncology and rare diseases positions Simbec-Orion as a preferred partner for niche therapies from mid-stage programs seeking specialized pharmacology and trial design, with proximity to major biotech hubs.